Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001214659-26-001398·Octagon Capital Advisors LP
Schedule 13G ownership disclosure
Unicycive Therapeutics, Inc.
Common Stock, $0.001 par value · CUSIP: 90466Y202
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Octagon Capital Advisors LP
Shares: 1,000,000.00 · Class: 4.7%
- Octagon Investments Master Fund LP
Shares: 650,000.00 · Class: 3.0%
- Octagon Biotech Opportunities Fund I LP
Shares: 350,000.00 · Class: 1.7%
- Ting Jia
Shares: 1,000,000.00 · Class: 4.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001214659-26-001398
- Form type
- SCHEDULE 13G/A
- Filer
- Octagon Capital Advisors LP
- CIK
- CIK 1839435
- Filed
- Feb 10, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership